We are analyzing https://link.springer.com/article/10.1007/s00262-024-03913-0.

Title:
Targeting BCMA in multiple myeloma: designs, challenges, and future directions | Cancer Immunology, Immunotherapy
Description:
Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the development of CAR T cell therapies designed to address this plasma cell cancer. Various CAR designs, utilizing different BCMA recognition domains, have yielded promising clinical results, leading to the approval of two BCMA-targeting CAR T cell therapies by the US Food and Drug Administration (FDA) for the treatment of MM. This review uniquely examines the BCMA CAR T cell landscape, emphasizing the design of recognition domains, clinical efficacy, and patient outcomes. It critically addresses emerging challenges such as antigen escape and toxicity profiles, which have surfaced alongside therapeutic advances. Moreover, the review spotlights cutting-edge developments, including dual-targeting CAR T strategies, advancements in CAR T cell manufacturing, and innovative allogeneic CAR T approaches utilizing healthy donor cells. By detailing both the breakthroughs and ongoing challenges in BCMA CAR T cell therapy, this review offers a comprehensive perspective on the current state and future possibilities of CAR T cell therapy for MM and its expanding role in treating hematologic malignancies and beyond.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Insurance
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

car, cells, patients, cell, article, google, scholar, bcma, pubmed, therapy, myeloma, multiple, antigen, cart, cas, study, phase, targeting, treatment, blood, central, cars, clinical, cancer, efficacy, potential, relapsed, refractory, grade, receptor, therapies, chimeric, response, domain, including, rrmm, median, crs, months, domains, results, trial, responses, safety, demonstrated, relapsedrefractory, design, expression, oncol, immunotherapy,

Topics {✒️}

anti-b-cell maturation antigen car-t-related peripheral neuropathy expected car-t-related effects minimize host-versus-graft rejection g-protein-coupled receptor class bcma car-t-cell therapy b-cell maturation antigen antigen-specific monoclonal antibody bcma/cd19 dual-targeting fastcar antibody-based binding moieties open-label single-arm study bi-specific antitumor activity car named fhvh33-cd8bbz predominantly α-helical structure full-length native protein extracellular antigen-binding domain article download pdf fda-approved bcma-directed car camelid single-domain antibody anti-cd38 monoclonal antibody potent anti-leukemia activities dual-antigen–expressing disease anti-bcma/gprc5d bispecific car car t-cell therapy dual-targeted cellular therapy full anti-bcma car antibody-fragment-based car recombinant expression systems anti-car antibody responses t-charge tm platform combining mono-targeted car graft-versus-host toxicity bcma-targeted biologic therapies fully human heavy-chain fully human heavy-chain fully-human heavy-chain rapid anti-myeloma activity ipsc-derived lymphocytes offer human open-label study myeloid-derived suppressor cells patients received p-bcma-allo1 refractory b-cell malignancies chimeric antigen receptor natural trimeric conformation patients undergoing bcma-targeted high-affinity ligand april receiving murine-based cd19car multi-specific car targeting single-chain variable fragment t-charge platform [104

Questions {❓}

Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeting BCMA in multiple myeloma: designs, challenges, and future directions
         description:Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the development of CAR T cell therapies designed to address this plasma cell cancer. Various CAR designs, utilizing different BCMA recognition domains, have yielded promising clinical results, leading to the approval of two BCMA-targeting CAR T cell therapies by the US Food and Drug Administration (FDA) for the treatment of MM. This review uniquely examines the BCMA CAR T cell landscape, emphasizing the design of recognition domains, clinical efficacy, and patient outcomes. It critically addresses emerging challenges such as antigen escape and toxicity profiles, which have surfaced alongside therapeutic advances. Moreover, the review spotlights cutting-edge developments, including dual-targeting CAR T strategies, advancements in CAR T cell manufacturing, and innovative allogeneic CAR T approaches utilizing healthy donor cells. By detailing both the breakthroughs and ongoing challenges in BCMA CAR T cell therapy, this review offers a comprehensive perspective on the current state and future possibilities of CAR T cell therapy for MM and its expanding role in treating hematologic malignancies and beyond.
         datePublished:2025-02-01T00:00:00Z
         dateModified:2025-02-01T00:00:00Z
         pageStart:1
         pageEnd:16
         license:http://creativecommons.org/licenses/by-nc-nd/4.0/
         sameAs:https://doi.org/10.1007/s00262-024-03913-0
         keywords:
            B cell maturation antigen
            Multiple myeloma
            Chimeric antigen receptor
            T cells
            Immunotherapy
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-024-03913-0/MediaObjects/262_2024_3913_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-024-03913-0/MediaObjects/262_2024_3913_Fig2_HTML.png
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
            volumeNumber:74
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yi Hu
               affiliation:
                     name:Shenzhen Children’s Hospital
                     address:
                        name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yuetao Xie
               affiliation:
                     name:Shenzhen Children’s Hospital
                     address:
                        name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiaodong Wang
               affiliation:
                     name:Shenzhen Children’s Hospital
                     address:
                        name:Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lufeng Yang
               affiliation:
                     name:Shenzhen Children’s Hospital
                     address:
                        name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:He Geng
               affiliation:
                     name:Shenzhen Children’s Hospital
                     address:
                        name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zugang Yi
               affiliation:
                     name:Shenzhen Children’s Hospital
                     address:
                        name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yao Zhang
               affiliation:
                     name:Shenzhen Children’s Hospital
                     address:
                        name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lin Ma
               affiliation:
                     name:Shenzhen Children’s Hospital
                     address:
                        name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fang Chen
               affiliation:
                     name:Shenzhen Children’s Hospital
                     address:
                        name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeting BCMA in multiple myeloma: designs, challenges, and future directions
      description:Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the development of CAR T cell therapies designed to address this plasma cell cancer. Various CAR designs, utilizing different BCMA recognition domains, have yielded promising clinical results, leading to the approval of two BCMA-targeting CAR T cell therapies by the US Food and Drug Administration (FDA) for the treatment of MM. This review uniquely examines the BCMA CAR T cell landscape, emphasizing the design of recognition domains, clinical efficacy, and patient outcomes. It critically addresses emerging challenges such as antigen escape and toxicity profiles, which have surfaced alongside therapeutic advances. Moreover, the review spotlights cutting-edge developments, including dual-targeting CAR T strategies, advancements in CAR T cell manufacturing, and innovative allogeneic CAR T approaches utilizing healthy donor cells. By detailing both the breakthroughs and ongoing challenges in BCMA CAR T cell therapy, this review offers a comprehensive perspective on the current state and future possibilities of CAR T cell therapy for MM and its expanding role in treating hematologic malignancies and beyond.
      datePublished:2025-02-01T00:00:00Z
      dateModified:2025-02-01T00:00:00Z
      pageStart:1
      pageEnd:16
      license:http://creativecommons.org/licenses/by-nc-nd/4.0/
      sameAs:https://doi.org/10.1007/s00262-024-03913-0
      keywords:
         B cell maturation antigen
         Multiple myeloma
         Chimeric antigen receptor
         T cells
         Immunotherapy
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-024-03913-0/MediaObjects/262_2024_3913_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-024-03913-0/MediaObjects/262_2024_3913_Fig2_HTML.png
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
         volumeNumber:74
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yi Hu
            affiliation:
                  name:Shenzhen Children’s Hospital
                  address:
                     name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yuetao Xie
            affiliation:
                  name:Shenzhen Children’s Hospital
                  address:
                     name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiaodong Wang
            affiliation:
                  name:Shenzhen Children’s Hospital
                  address:
                     name:Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lufeng Yang
            affiliation:
                  name:Shenzhen Children’s Hospital
                  address:
                     name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:He Geng
            affiliation:
                  name:Shenzhen Children’s Hospital
                  address:
                     name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zugang Yi
            affiliation:
                  name:Shenzhen Children’s Hospital
                  address:
                     name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yao Zhang
            affiliation:
                  name:Shenzhen Children’s Hospital
                  address:
                     name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lin Ma
            affiliation:
                  name:Shenzhen Children’s Hospital
                  address:
                     name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fang Chen
            affiliation:
                  name:Shenzhen Children’s Hospital
                  address:
                     name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
      volumeNumber:74
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Shenzhen Children’s Hospital
      address:
         name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Shenzhen Children’s Hospital
      address:
         name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Shenzhen Children’s Hospital
      address:
         name:Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Shenzhen Children’s Hospital
      address:
         name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Shenzhen Children’s Hospital
      address:
         name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Shenzhen Children’s Hospital
      address:
         name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Shenzhen Children’s Hospital
      address:
         name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Shenzhen Children’s Hospital
      address:
         name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Shenzhen Children’s Hospital
      address:
         name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yi Hu
      affiliation:
            name:Shenzhen Children’s Hospital
            address:
               name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Yuetao Xie
      affiliation:
            name:Shenzhen Children’s Hospital
            address:
               name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Xiaodong Wang
      affiliation:
            name:Shenzhen Children’s Hospital
            address:
               name:Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Lufeng Yang
      affiliation:
            name:Shenzhen Children’s Hospital
            address:
               name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:He Geng
      affiliation:
            name:Shenzhen Children’s Hospital
            address:
               name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Zugang Yi
      affiliation:
            name:Shenzhen Children’s Hospital
            address:
               name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Yao Zhang
      affiliation:
            name:Shenzhen Children’s Hospital
            address:
               name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Lin Ma
      affiliation:
            name:Shenzhen Children’s Hospital
            address:
               name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Fang Chen
      affiliation:
            name:Shenzhen Children’s Hospital
            address:
               name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
      name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
      name:Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China
      name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
      name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
      name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
      name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
      name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China
      name:Department of Anesthesiology, Shenzhen Children’s Hospital, Shenzhen, China

External Links {🔗}(354)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.73s.

LINK . SPRINGER . COM {}